Tempest Therapeutics, Inc. — Director's Dealing 2014

Jun 18, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2014-06-13

Reporting Person: Malley Thomas (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-06-13	Stock Option (right to buy)	$8.43	A	6500	Acquired	2024-06-13	Common Stock (6500)	Direct

Footnotes

F1: The stock option will vest in twelve equal monthly installments at the end of each successive month following June 13, 2014.